Last week, pharma giant Schering-Plough
Johnson & Johnson
On Friday, Schering also announced that blockbuster drug Zetia would begin marketing in Japan today. Zetia received the thumbs-up from the Japanese regulatory authorities in April. In conjunction with Remicade, these two compounds will steer the future of Schering's financial performance for the next several years.
Investors often overlook the importance that markets outside the U.S. offer for pharmaceutical products. Japan, for instance, is the second-largest market for pharmaceutical sales in the world when ranked by country.
For Schering-Plough, places like the EU and Japan represent a large chunk of its overall sales, with 60% of its $10.6 billion in sales coming outside the United States. This dependence on foreign markets will only grow with these positive developments for its two top drugs.
Looking for more Foolish drug stock coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations, as well as get access to our message boards and exclusive content, with a 30-day free trial.